TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker

Grant

Date/time Interval

  • November 25, 2014 - November 24, 2019

    • Awarded By

    Total Award Amount

  • 87926.00

    • Direct Costs

  • 69783.00

    • Sponsor Award Id

    • Contributor

  • Nabell M.D., Lisle   Investigator  
  • Rocque M.D., Gabrielle   Investigator  
  • Salvador M.D., Carolina   Investigator  
  • Stringer-Reasor M.D., Erica   Investigator